Therapeutics for Moderate and Severe Dengue

Starting soon · Phase 3 · Has a placebo group

Conditions studied: Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA Virus Infections, Hemorrhagic Fever

In brief

The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.

Key facts

Study ID
NCT07543458
Run by
Oxford University Clinical Research Unit, Vietnam
People needed
8800
Starts
2026-10-01
Expected to finish
2031-07-31
Last updated by the study team
2026-04-21

Who can join

Age: 5 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.